版本:
中国

BRIEF-Corbus announces last subject enrolled in Phase 2 study of anabasum

May 11 Corbus Pharmaceuticals Holdings Inc

* Corbus pharmaceuticals announces last subject enrolled in phase 2 study of anabasum for the treatment of skin-predominant dermatomyositis

* Corbus pharmaceuticals holdings inc- company expects topline results from study to be available in q4 of 2017. Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐